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and for the PhenX RISING networkAbstract
Background: The purpose of this manuscript is to describe the PhenX RISING network and the site experiences in
the implementation of PhenX measures into ongoing population-based genomic studies.
Methods: Eighty PhenX measures were implemented across the seven PhenX RISING groups, thirty-three of which
were used at more than two sites, allowing for cross-site collaboration. Each site used between four and 37
individual measures and five of the sites are validating the PhenX measures through comparison with other study
measures. Self-administered and computer-based administration modes are being evaluated at several sites which
required changes to the original PhenX Toolkit protocols. A network-wide data use agreement was developed to
facilitate data sharing and collaboration.
Results: PhenX Toolkit measures have been collected for more than 17,000 participants across the PhenX RISING
network. The process of implementation provided information that was used to improve the PhenX Toolkit. The
Toolkit was revised to allow researchers to select self- or interviewer administration when creating the data
collection worksheets and ranges of specimens necessary to run biological assays has been added to the Toolkit.
Conclusions: The PhenX RISING network has demonstrated that the PhenX Toolkit measures can be implemented
successfully in ongoing genomic studies. The next step will be to conduct gene/environment studies.
Keywords: PhenX, Phenotype, Epidemiology, Risk factors, HarmonizationBackground
The PhenX (consensus measures for Phenotypes and
eXposures) Toolkit (www.phenxtoolkit.org) is a set of
validated measures across 21 research domains that
can be used to facilitate cross-study comparisons to
increase statistical power to study gene/environment in-
teractions [1,2]. The National Human Genome Research
Institute (NHGRI) issued administrative supplements for
the addition of PhenX measures into existing population-
based genomic studies sponsored by NIH to evaluate
the usefulness of the PhenX measures and to stimulate
their uptake (http://grants.nih.gov/grants/guide/notice-files/
NOT-HG-11-009.html). Seven research groups were funded
through this granting mechanism, coming together to form* Correspondence: cmccarty@eirh.org
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reproduction in any medium, provided the orthe PhenX RISING (Real world Implementation and
ShaRING) consortium. The purpose of this manuscript is
to describe the network and the site experiences in
the implementation of PhenX measures into ongoing
population-based genomic studies. The information gained
will be used to further improve the PhenX Toolkit and to
provide guidance to other scientists seeking to incorporate
PhenX measures in their studies.Methods
The PhenX RISING consortium comprises seven groups.
A network-wide data use agreement was written and im-
plemented to facilitate transfer of de-identified data
among the seven groups and NHGRI. It is available on
the PhexX Toolkit website (https://www.phenxtoolkit.
org/index.php?pageLink=phenxrising). Research Triangle
Institute (RTI) International (Research Triangle Park,
North Carolina) serves as the administrative coordinatorl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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national documented PhenX protocol changes at each site.
Monthly teleconferences between NHGRI, RTI International
and the seven groups were used to share implementation
findings and to discuss cross-study collaborations. Institu-
tional certification was obtained from all sites to share
de-identified data collected for this project with dbGaP
(database of Genotypes and Phenotypes).
Site-specific information is summarized in Table 1.
Eighty PhenX measures were implemented across the
seven PhenX RISING groups, thirty-three of which were
used at more than two sites, allowing for cross-site collab-
oration (Table 2). The PhenC Toolkit contains ID num-
bers for the measures and separate numbers (often ending
in 1) for the detailed protocols for specific measures.
Each site used between four and 37 individual mea-
sures and five of the sites validated the PhenX measures
against other study measures (all but Asian Indian Dia-
betic Heart Study and Chinese Longitudinal Healthy
Longevity Survey). Eight of the measures were only col-
lected at a single site. Measures were selected to aug-
ment the data already available for the specific study
cohorts and outcomes. Some sites also included add-
itional measures to allow comparison across PhenX RIS-
ING sites. The following section contains descriptions of
the seven sites, the PhenX measures employed and the
administration of protocols for each site.
The Asian Indian Diabetic Heart Study/Sikh Diabetes
Study (AIDHS/SDS)
The AIDHS/SDS was established in India in 2002 and
was funded by Fogarty International Center of National
Institute of Health (NIH) [3]. Of the currently available
4,510 subjects from Phases I & II of the AIDHS/SDS,
1,200 subjects belong to family cohort and remaining
3,310 subjects are unrelated diabetic and healthy individ-
uals recruited from India and the US. The goals of AIDHS/
SDS are to discover unique genetic markers associated with
type 2 diabetes (T2D) and related metabolic and lipid traits
by performing genome-wide association scans (GWAS)
and validation studies. All participants signed a written in-
formed consent for these investigations. The AIHDS/SDS
was reviewed and approved by the University of Oklahoma
Health Sciences Center’s Institutional Review Board, as
well as the Human Subject Protection Committees at the
participating hospitals and institutes in India. Institutional
certification was obtained for the submission of genotype
and phenotype data of AIDHS to dbGaP.
Men and women aged 25–79 years participated. The
diagnoses of T2D were confirmed by reviewing medical
records for symptoms, use of medication, and measuring
fasting blood glucose (FBG) levels following the guide-
lines of the American Diabetes Association (2004) [4], as
described previously [5]. The 2 h oral glucose tolerancetest (OGTT) was performed following the criteria of the
World Health Organizations (WHO) (75 g oral load of glu-
cose). BMI was calculated as (weight [kg]/height [meter]
[4]). Subjects with type I diabetes, or those having a family
member with type I diabetes, or rare forms of T2D
sub-types (maturity onset diabetes of young [MODYs]),
or secondary diabetes (from e.g. hemochromatosis, pan-
creatitis) were excluded from the study. The selection of
controls was based on a fasting glycemia < 100.8 mg/dL
(< 5.6 mmol/L) or 2 h glucose <141.0 mg/dL (< 7.8 mmol/L)
were clinically free of T2D, impaired glucose toler-
ance (IGT).
Fasting blood samples (overnight, 12 hr) were drawn by
trained assistants and serum and plasma aliquots were
prepared for storage at −80°C. Blood pressure, anthropo-
metric measurements (height, weight, and waist to hip ra-
tio), FBG, insulin, serum cholesterol (total, HDL-C and
LDL-C, and triglycerides) have been measured on all par-
ticipants as described previously [5,6].
A GWAS was performed on 1,983 AIDHS/SDS sub-
jects (980 T2D cases and 1,003 controls) from Punjabi
Sikh community using a Human660W-Quad BeadChip
arrays (Illumina, USA). Frozen serum samples of 1,983
subjects with GWAS data are used to perform biomarker
estimations in the PhenX RISING study. We measured
biomarkers related to beta cell function (c-peptide, total
amylin), obesity (leptin), inflammation (TNF-α, MCP-1),
T2D (vitamin D-25-OH), and kidney function (creatinine).
These assays were performed following protocols and
basic specifications in the PhenX Toolkit (http://www.
phenxtoolkit.org/) to aid compatibility across different
studies. The multiplex assays for c-peptide, leptin, total
amylin, TNF- α, and MCP-1 were performed using
Magnetic MILLIPLEX Human Metabolic panel from
Millipore (St. Charles, Missouri) on Luminex platform
(PhenX protocol #141201). The assays for 25-OH vitamin
D (PhenX protocol #051100) were performed using stand-
ard monoclonal antibody-based florescence ELISA assays
kits from ALPCO Diagnostics (Salem, NH). Serum cre-
atinine was measured at Oklahoma University Medical
Center Laboratory using standard Jaffe rate methodology
according to the PhenX protocol (141201). All assay kits
for each biomarker were used from a single source.
Detroit Neighborhood Health Study – University of
Michigan
The Detroit Neighborhood Health Study (DNHS) is a
prospective, representative longitudinal cohort study of
predominantly African American adults living in Detroit,
Michigan. The overall goal of the DNHS is to identify
how genetic variation, lifetime experience of stressful
and traumatic events, and features of the neighborhood en-
vironment predict psychopathology and behavior. As such,
the study includes two parts: a neighborhood assessment
Table 1 PhenX RISING cohort descriptions, administration protocol and issues identified across the seven sites
Site Cohort description Administration Time to administer Issues identified during administration/protocol
changes made
Asian Indian Diabetic
Heart Study/SIKH
Diabetes Study
(AIDHS/SDS)
4,510 subjects aged 25+; 1,983 available
with GWAS
Recruited by study staff, free health check-up and
cholesterol/glucose lab results incentive; PhenX
biomarker data collected using frozen sera
40-45 minutes Not applicable
Detroit Neighborhood
Health Study (Detroit)
800 subjects aged 18+ from population
representative Detroit Neighborhood Health
Study cohort with GWAS data
Telephone administered, $25 incentive 32.3 minutes
(average)
Formatting to change instructions for telephone
administration and CATI, coding, drop annual family
income question due to errors
Duke University
Imaging and Genetics
(Duke)
200 college students and 50 adolescents.
Genotyping for COMT Val Met genotype
(rs4680) DAT gene (SLC6A3)
Computer-administered 60 minutes Conversion to electronic format was difficult for some
PhenX measures, but worth the investment
Experimenter administered, data collected by
computer
Marshfield Clinic
Personalized Medicine
Research Project
(PMRP)
3344 subjects aged 50+ from population-
based biobank with GWAS data for age-
related cataract, HDL, dementia, glaucoma;
aged 39–100, 98% European American, 60%
female
Self-administered, mailed to non-
institutionalized subjects, $10 incentive
20-40 minutes Formatting to remove instructions for person
administering and scoring questionnaire, inconsistency
of response order (no/yes, yes/no), skip logic errors,
rules for coding
Pediatric Imaging
Neurocognition and
Genetics (PING)
284 subjects ages 9–21 recruited from 6 sites
across the U.S. and 77 subjects from San Diego
ages 3–7, all with GWAS data and neural
architectural and neurocognitive phenotypes,
64% European American, 51% male
Self-administered, web-based format completed
at home for retrospective cases and in the lab or
at home for prospective cases, reimbursements
varied by site and ranged from $20 to $40;
parents of participants ages 3–7 completed the
CBQ in the lab
20-90 minutes Changed wording slightly for a few questions to make
them applicable to all PING age groups, changed item
orders when necessary for skip logic to work, scored
short form domains using means instead of sums
because of missing data
UCLA Consortium for
Neuropsychiatric
Phenomics
278 completed on-line protocol and 114
completed in-lab protocol; recruited from
840 eligible; ages 21–50; English speaking
Web-based questionnaires (445 questions) for
on-line protocol; paper and pencil tests for
in-lab protocol
60 minutes on-line;
60 minutes in-lab
Conversion to on-line administration involved some
modifications to wording and logic
Chinese Longitudinal
Healthy Longevity
Survey (CLHLS)
In our CLHLS 2011–2012 wave, we plan to
follow-up interview those CLHLS subjects
aged 65+ who were interviewed in
2008–2009 wave. We have newly added 13
PhenX measures (including 32 data items)
in our CLHLS 2011–2012 new wave
Home-based face-to-face interviews, with a gift
of about $4. Up to middle March 2012, we have
conducted interviews with 7,475 surviving
CLHLS participants, and 4,914 interviews with a
close family member of the deceased CLHLS
Participants. So far, the response rate is 84.58%,
lost-follow-up rate is 13.01%, and the refusing
rate is 2.41%
About 1.5 hours To meet the aims of this PhenX administrative
Supplement project, we modified our previous CLHLS
protocol by newly adding data collection of the 13
PhenX measures, including 32 data items
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Table 2 PhenX measures being implemented across PhenX RISING sites
PhenX ID Measures Detroit
neighborhood
health study
UCLA PING PMRP AIDHS/SDS Duke CLHLS # Groups with
this measure
in Common
010100 Current age XM Z X*, XM X*, XM Z XM Z 7
011000 Current educational attainment XM Z Z X*, XM Z XM Z 7
010900 Current marital status XM Z X*, XM X*, XM Z XM X 7
010500 Ethnicity XM Z Z X*, XM Z X Z 7
010700 Gender XM Z X*, XM X*, XM Z XM X 7
011300 Current employment status XM Z X*, XM Z XM Z 6
120500 Depression Z X X*, XM X* Z XM 6
010600 Race XM Z Z X*, XM X XM 6
030300 Alcohol - 30-day quantity and frequency Z XM X* XM Z 5
020600 Hand dominance Z Z X*, XM Z X 5
030800 Tobacco - 30-day quantity and frequency Z XM X* XM Z 5
030200 Alcohol - age of first use XM X*, XM X X 4
030500 Alcohol - lifetime abuse and dependence XM X*, XM X X 4
030100 Alcohol - lifetime use XM X*, XM Z X X 4
010200 Birthplace X* Z XM XM 4
040100 Family history of heart attack XM X*, XM Z X 4
030800 Substances - 30-day frequency X*, XM XM XM X* 4
031100 Substances - lifetime use X*, XM Z XM XM 4
030900 Tobacco - age of offset of use XM X* XM XM 4
031000 Tobacco - nicotine dependence XM X*, XM X X 4
030600 Tobacco - smoking status XM X* Z XM 4
030400 Alcohol - maximum drinks in 24 hours XM X*, XM X 3
011100 Annual family income Z Z Z X 3
010400 Birthplace of grandparents X Z XM 3
010800 Current address X*, XM Z XM 3
060700 Current environmental tobacco smoke
exposure
X*, XM Z X 3
180600 General self-efficacy screener X XM XM 3
011500 Health insurance coverage XM X*, XM X 3
130300 History of stroke - ischemic infarction and
hemorrhage
X*, XM Z X 3
180800 Perceived stress X XM XM 3
060800 Sibship/Birth order Z X*, XM X 3
030700 Tobacco - age of initiation of use XM X* XM 3
131000 Working memory X Z Z 3
121500 ADHD symptoms X XM 2
060100 Characteristics of current residence X*, XM X 2
210200 Child-reported parental education attainment Z XM 2
180400 Disinhibiting behaviors/Impulsivity X X*, XM 2
120600 Eating disorders screener X X*, XM 2
180500 Emotional state X XM 2
131100 Executive function X Z 2
121300 General distress X XM 2
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Table 2 PhenX measures being implemented across PhenX RISING sites (Continued)
020704 Height (self-reported) X*, XM X 2
020703 Height (standing) Z X 2
120400 Hypomania/Mania symptoms X X 2
101100 Menstrual history XM Z 2
121100 Personality traits X Z 2
121600 Psychopathy X XM 2
180900 Self-esteem X XM 2
181000 Social isolation X XM 2
030900 Substances - age of first use XM XM 2
031400 Substances - lifetime abuse and dependence Z XM N 2
120900 Symptoms of autism spectrum disorder X XM 2
150900 Total physical activity screener X XM 2
130900 Visual memory X Z 2
021600 Waist circumference Z XM 2
021502 Weight (self-reported) X XM 2
180100 Acculturation X 1
120200 Anxiety disorders screener X*, XM 1
160200 Assay for cytokine panel 12 X 1
210100 Childhood maltreatment XM 1
100300 Contraceptive methods XM 1
180300 Current quality of life XM 1
141200 Fasting C-peptide assay for residual beta cell
function
X 1
130700 Global mental status screener X 1
101000 Male sexual function XM 1
70300 Passive smoke exposure XM 1
180700 Perceived social support/conflict X 1
201500 Personal and family history of hearing loss XM 1
070700 Personal perception and knowledge of
smoking-related cancer risk
XM 1
211000 School social environment X*, XM 1
141400 Serum creatinine for kidney function X 1
101400 Sexual history XM 1
211100 Social networks X 1
081500 Toothache and orofacial pain X 1
150702 Total physical activity (adult) Z 1
150703 Total physical activity (older adult) Z 1
061300 Ultraviolet light exposure X*, XM 1
130800 Verbal memory X 1
051100 Vitamin D X 1
021501 Weight (measured) Z 1
12 21 26 34 4 37 35
LEGEND
X = PhenX measure.
X* = PhenX measure with changes to the protocol.
XM = PhenX measure with change to mode of administration.
Z = similar data available, but not collected with PhenX.
N = Dropped.
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Detroit neighborhoods was conducted June-July 2008.
Data was collected on various aspects of neighborhoods,
such as external building condition, sidewalk/street condi-
tion, presence of graffiti, presence of community gardens,
and number of vacant lots. Cohort participants were se-
lected with a dual-frame probability design, using telephone
numbers obtained from the U.S. Postal Service Delivery
Sequence Files as well as a listed-assisted random-digit-
dial frame [7]. Individuals without listed landlines or tele-
phones and individuals with only a cell phone listed were
invited to participate through a postal mail effort. Partici-
pants completed a 40 minute structured telephone inter-
view annually between 2008–2012 to assess perceptions
of participants’ neighborhoods, mental and physical
health status, social support, exposure to traumatic events,
and alcohol and tobacco use; each participant was com-
pensated $25USD [7,8]. All survey participants were of-
fered the opportunity to provide a blood specimen
(venipuncture, blood spot, or saliva) for immune and
inflammatory marker testing as well as genetic testing
of DNA [9]. Participants received an additional $25USD
if they elected to give a sample. Informed consent was ob-
tained at the beginning of each interview and again at spe-
cimen collection. The Institutional Review Board of the
University of Michigan reviewed and approved the study
protocol.
Of the 1,547 participants in Wave 1 (Sept. 2008- April
2009) and Wave 2 (Sept. 2009- June 2010), 917 provided
a biospecimen sample yielding DNA; 800 were ran-
domly selected for GWAS testing using the Illumina
OmniExpress GWAS chip. The fourth wave of the DNHS
interview incorporated PhenX Toolkit phenotype mea-
sures (Table 2) and targeted these 800 individuals. Institu-
tional certification was obtained for the deposition of
genetic and phenotypic data into dbGaP.
Identifying and modifying a risk phenotype for
self-regulation failure - Duke University
The parent study was designed to validate a hypothe-
sized gene/environment/self-regulation risk phenotype
(a combination of individual differences in regulatory
focus, COMT genotype, and chronic failure to attain a
particular kind of personal goal) that is believed to con-
fer vulnerability to failures of self-regulation, which in
turn increase risk for psychopathology with significant
public health implications such as aggression, gambling,
and excessive use of alcohol and other drugs. The parent
study includes the best-validated measures in the field of
imaging genetics for quantifying the phenotypes of inter-
est. This list shares little overlap with the specific measures
included in the PhenX toolkit, but significant overlap in the
domains of interest including Psychiatric, Psychosocial, and
Alcohol, Tobacco, and Other Substances. Conceptuallyoverlapping measures from these domains were integrated
into our existing protocol, allowing for evaluation of rela-
tionships between PhenX toolkit measures and behavioral,
clinical, neural, hormonal and genetic variables of clear
significance for psychopathology. Thus, the broad goals of
our proposed research are (1) to add measures from the
PhenX toolkit that overlap with phenotypic measures in
the existing study and (2) to add measures from the
PhenX toolkit that represent important areas of measure-
ment that were not included in the parent grant because
they were not specifically related to the aims of that inves-
tigation. We will then evaluate the utility of PhenX
toolkit measures on several criteria including valid-
ation against intermediate neurobiological phenotypes
identified through functional neuroimaging.
Over the 1-year funding period, we collected data on
N = 200 subjects from a college sample and N = 50 sub-
jects from an adolescent sample. All subjects were re-
cruited through existing protocols approved by the Duke
University Medical Center Institutional Review Board
and provide written informed consent before participa-
tion. We will now work with collaborators to combine
our data sets with others that have used the same PhenX
tools to provide the greatest power possible to address
questions of genetic influences on phenotypes of interest
to our colleagues in the field as well as those pheno-
types most directly related to our own work. Of note,
we anticipate continuing to use the added PhenX mea-
sures for the duration of the parent project, giving a
total sample size of N = 400 college students and N = 100
adolescents.
Marshfield Clinic Personalized Medicine Research Project
(PMRP)
The Marshfield Clinic Personalized Medicine Research
Project (PMRP) is a population-based biobank linked to
the electronic health records of Marshfield Clinic [10].
After providing written informed consent, subjects aged
18 years and older completed questionnaires that in-
cluded questions on demographics, family health history,
smoking and alcohol exposure and dietary intake [11]
and physical activity questionnaires. The biobank was
reviewed and approved by the institutional review board
(IRB) of Marshfield Clinic. The PhenX RISING project
was reviewed and approved by the IRBs at Essentia Insti-
tute of Rural Health, Marshfield Clinic and Pennsylvania
State University.
The Marshfield Clinic PMRP is a member of the NHGRI-
funded eMERGE network (www.gwas.net) [12]. The goal
of eMERGE1 was to conduct genome-wide association
studies using electronic health records to define pheno-
type. The primary Marshfield phenotypic outcomes used
to identify subjects for GWAS genotyping were age-related
cataract and HDL. Additional subjects were genotyped for
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coma. The subjects with GWAS data who were alive with
known, non-institutionalized addresses and who had given
consent for re-contact were eligible for participation in
the PhenX RISING study.
The PhenX measures listed in Table 2 from the PhenX
Toolkit were incorporated into a 32-page, self-administered
questionnaire. The questionnaires were mailed with a cover
letter to eligible subjects with a stamped, self-addressed en-
velope. A second mailing was employed to maximize the
response rate. Subjects were offered $10 for their time to
complete the questionnaire. PhenX responses were vali-
dated using data from PMRP questionnaires and Marsh-
field Clinic electronic health records [13].
Pediatric Imaging, Neurocognition, and Genetics (PING)
Pediatric Imaging, Neurocognition, and Genetics (PING)
is a multi-site cross-sectional study of typically develop-
ing children, adolescents, and young adults ranging in
age from 3 to 20 (see Acknowledgements for a descrip-
tion of participating members from the PING infrastruc-
ture) funded by the National Institute on Drug Abuse
(NIDA) and the National Institute of Child Health and
Human Development (NICHD). The primary goal of
PING is to create a pediatric imaging-genomics database
of approximately 1400 cases that is freely available to the
scientific community. Participants aged 18 and up provided
written informed consent to undergo approximately three
hours of neurocognitive testing and a one hour neuroimag-
ing session, and to provide a saliva sample for [14,15]. The
majority of participants also consented to allow these data
to be shared in the publicly available database. For partici-
pants under the age of 18, parent versions of this consent
were signed and the children and adolescents provided
their assent where appropriate. This study structure was
approved by IRBs at all participating PING sites. Six of the
9 PING sites chose to participate in the PhenX RISING
project, and each participating site’s IRB approved this
project as well.
Initially, only self-report PhenX measures were chosen
for inclusion in PING. Given the reading limitations of
the youngest children in the PING age range, only par-
ticipants ages 9 and above were asked to complete these
measures. Although the original PING age range was 3
to 20, a few of the participants were 22 years old by the
time they were brought back to complete the PhenX
measures. Between the 6 sites who opted to participate in
the PhenX RISING project, 585 subjects met the initial
age criteria for inclusion. Subsequently, the UC San Diego
site opted to include data from one PhenX parent-report
measure (Childhood Behavior Questionnaire; CBQ) that
they were already administering in the lab for 3 to 7 year
old participants prior to beginning the PhenX RISING
project. Table 2 lists all the PhenX measures that werechosen for inclusion. Not all of the original measures were
deemed appropriate for all ages. As such, study arms were
created for different age ranges, and measures were in-
cluded in each age range as appropriate. Table 3 indicates
which measures were used in each study arm. Several
PhenX instruments were available in both child/adoles-
cent and adult versions. With one exception, child/adoles-
cent versions were used for all participants in order to
maximize consistency across PING cases. Separate ver-
sions were used only for the General Self-Efficacy scale be-
cause the child version asked a large number of school-
related questions that were not appropriate for young
adults. Some questions were modified from their original
form in order to broaden their applicability to all partici-
pants within the PING age range (see Table 4 for specific
modifications).
Although PING recruitment strategies varied by site,
the general approach that was taken was to enroll and
complete participants in the older age ranges first. This
strategy allowed investigators to observe responses to
testing and imaging, and to better anticipate and plan
for any challenges that seemed likely to arise when run-
ning younger subjects. PhenX Toolkit measures were
not incorporated into PING data acquisition protocols
until most children over age 8 were already completed. As
such, the time between collection of the initial PING de-
liverables and the collection of PhenX data varied greatly
for participants who were enrolled in PING after the
addition of the PhenX protocol. Overall, the time differ-
ence ranged from 0 to 2.5 years (M = 0.93, SD = 0.76). Par-
ticipants who were adolescents when they assented to
participation in PING, but then turned 18 prior to PhenX
completion, were asked to complete an additional adult
consent form.
In order to improve response rate from participants
who already completed PING, it was decided that PhenX
data would be completed in a web-based format. An NIH-
sponsored web-based data collection tool called Assessment
Center (www.assessmentcenter.net) was used for online data
collection. A multi-arm study was created in Assessment
Center, with each arm representing an age range, and the
PhenX instruments were added to the study arms as ap-
propriate. Items appeared on the screen one at a time,
and participants could choose a response option or press
“Next” to skip to the next question. Participants could also
click “Previous” to go back and change a response to a
previous item within an instrument. The structure of the
alcohol and substance abuse instruments was changed
slightly, and skip logic was employed, in order to adapt
them to the web-based format.
Participant recruitment and reimbursement strategies for
the PhenX RISING project varied by PING site. For retro-
spectively collected cases, some sites called or emailed
participants or parents and offered an opportunity to
Table 3 PhenX measures being implemented in PING by study arm
Study arm (age range)
PhenX toolkit measure 9-10 11 12-13 14-17 18-21
Demographics - age (#010101) ✔ ✔ ✔ ✔ ✔
Demographics - gender (#010701) ✔ ✔ ✔ ✔ ✔
Demographics - marital status (#010901) ✔
Emotional state, child protocol (#180502) ✔ ✔ ✔ ✔ ✔
Depression, child protocol (#120501) ✔ ✔ ✔ ✔ ✔
Anxiety disorders screener, child protocol (#120201) ✔ ✔ ✔ ✔ ✔
Disinhibiting behaviors - impulsivity, child protocol (#180402) ✔ ✔ ✔ ✔
General self-efficacy, adult protocol (#180601) ✔
General self-efficacy, child protocol (#180602) ✔ ✔ ✔
School social environment (#211001) ✔ ✔ ✔ ✔
Tobacco - 30-day quantity and frequency (#030801) ✔ ✔ ✔
Tobacco - age of initiation of use (#030701) ✔ ✔ ✔
Tobacco - age of offset of use (#030901) ✔ ✔ ✔
Tobacco - smoking status (#030601) ✔ ✔ ✔
Tobacco - nicotine dependence (#031001) ✔ ✔ ✔
Perceived stress (#180801) ✔ ✔
Self-esteem (#180901) ✔ ✔
Alcohol - 30-day quantity and frequency (#030301) ✔ ✔
Alcohol - age of first use (#030201) ✔ ✔
Alcohol - lifetime abuse and dependence (#030501) ✔ ✔
Alcohol - lifetime use (#030101) ✔ ✔
Alcohol - maximum drinks in 24 hours (#030401) ✔ ✔
Substances - age of first use (#031201) ✔ ✔
Substances - lifetime abuse and dependence (#031401) ✔ ✔
Substances - lifetime use (#031101) ✔ ✔
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brought participants back into the lab for additional studies,
and asked them to complete the web-based PhenX study at
that time. Sites also differed on prospective data collection
procedures, where some collected PhenX data in lab and
others allowed participants to complete the questionnaire
from home. When login information was emailed to partic-
ipants, a username was sent in an email with the study link,
and a password was sent in a separate email for security
purposes. Reimbursements were sent after verification of
completion, and ranged from $20 to $40.
UCLA Consortium for Neuropsychiatric Phenomics
The Consortium for Neuropsychiatric Phenomics com-
prises eight linked grants awarded under the aegis of the
NIH Roadmap Initiative. The PhenX supplement grant
was awarded to the Human Translational Applications
Core, a center core that conducted extensive phenotyp-
ing of more than 1000 healthy volunteers aged 21 to 50
in the Los Angeles metropolitan area from 2007 to 2012.The phenotyping efforts focused on two primary themes –
memory mechanisms and response inhibition mecha-
nisms – and participants completed approximately
12 hours of cognitive phenotyping, and a subset of these
participants received also several hours of neuroimaging
procedures to examine brain structure and function
(descriptions of these procedures are available at www.
phenomics.ucla.edu). The PhenX supplement to this proto-
col focused on behavioral and cognitive variables, and in-
volved two components: (1) a Web-based component
comprising participant self-report questionnaires, which
was offered to all English-speaking completers of the
parent study who agreed to be recontacted; and (2) an in-
laboratory study English-speaking completers who were
willing to have additional procedures conducted in the la-
boratory. These measures are listed in Table 2. Partici-
pants received $15/hour for participating and those who
came for in-lab procedures additional received reimburse-
ment for public transportation or parking. The project
was approved by the UCLA IRB.
Table 4 PhenX protocol changes implemented by sites
PhenX ID Description of protocol change Group
120600 Had to add ‘0’ option for how many times the person throws up because there was no skip logic Duke
030300 Did not modify “Protocol Text” field but modified other fields (frequency, used “everday” instead of
“every 30 days”)
CLHLS
010100 Did modify “Protocol Text” field for specific applications (added “animal year” for birth year) CLHLS
011000 Did modify “Protocol Text” field for specific applications (added “the year of attending school” instead of
the degree of education)
CLHLS
011300 Did modify “Protocol Text” field for specific applications (most of respondents are retired at present) CLHLS
010500 Did modify “Protocol Text” field for specific applications (respondents are Chinese, not Americans) CLHLS
101100 Did not modify any fields but used a subset of the protocols CLHLS
030800 Did not modify “Protocol Text” field but modified other fields (frequency, used “everday” instead of
“every 30 days”)
CLHLS
150703 Did modify “Protocol Text” field for specific applications (added “playing mah-jong”) CLHLS
011100 Unfortunately, we had to drop the PhenX family income measure. If the participant does not outright
answer their best estimate for total family income, a series of higher or lower questions are asked which
relies on poverty threshold information determined by the US Census Bureau. However, the poverty
threshold levels contradict the pre-determined series of higher or lower questions such that a family could
be making more than $30 K a year but still be under the poverty threshold depending on the number of
members living in the household. Thus, we felt this question was subject to error and we decided to revert
to the family income question asked in previous waves of our survey. (See attached word document)
Detroit
Neighborhood
Health Study
031100 For the Substance use questions, we decided in conjunction with our survey company to alter these
questions for administration simplicity, while ultimately still obtaining the answers for the PhenX
questions. First, we ask about ANY use of the 10 categories of substances for both lifetime and 30 day
frequency. Then, we ask about ILLICIT use for lifetime and 30 day frequency.
Detroit
Neighborhood
Health Study
030800 For the Substance use questions, we decided in conjunction with our survey company to alter these
questions for administration simplicity, while ultimately still obtaining the answers for the PhenX
questions. First, we ask about ANY use of the 10 categories of substances for both lifetime and 30 day
frequency. Then, we ask about ILLICIT use for lifetime and 30 day frequency.
Detroit
Neighborhood
Health Study
010100 Changed “refused” response option to “decline to state” PING
010700 Changed “refused” response option to “decline to state” PING
010900 Changed “refused” response option to “decline to state” PING
180400 Did not modify any protocol text, but modified the age range such that the child version will be given
to all participants (up to age 21)
PING
211000 Added instructions and a question at the beginning asking for an education level so that the questionnaire
could be administered to only the participants who are still in school. Also changed wording of items 7
(“help us children with our…” to “help students with their…”), 9 (“teacher” to “teachers”), and 37
(“when we play” to “when we do activities”) in order to make it apply to entire age range.
PING
120500 Administering the child protocol to all participants ( up to age 21). Also modified wording of items 4
(“other kids” to “others”) and 15 (“kids” to “people”) in order to make it applicable to entire age range.
PING
120200 Administering child version to all participants (up to age 21). Changed the wording of items 6 (“I want
that things are in a fixed order” to “I want things to be in a fixed order”), 52 (“I worry that bad happens
to my parents” to “I worry that bad things happen to my parents”), and 64 (“I have unbidden thoughts
about a very aversive event I once experienced” to “I have unwanted thoughts about a very unpleasant
event I once experienced”) in order to make them more easily understood by young children.
PING
All Alcohol, Tobacco,
& Substance
Questionnaires
Administered all questions, but added questions and modified order when necessary to allow for the
skip logic to work properly in Assessment Center. Will be emailing reference cards as separate files in
email to participants.
PING
180500 Did not modify any protocol text, but modified the age range such that the child version will be given
to all participants (up to age 21)
PING
030300 Removed don’t know/refused option and from [DATEFILL] not used, cards not used PMRP
030200 No changes, definition/cards not given PMRP
030100 No changes, definition/cards not given PMRP
030500 No don’t know/refused option, did not include question 3 as had just answered largest number of drinks
in a single day, did not use skip for 3 or fewer drinks or questions 1 and 2 never, just continued with
tolerant questions, included card E2 for them to determine 50% increase or not, put YES as first option
to keep consistent throughout, removed tally sheet references, did not include question 5.2a as no don’t
PMRP
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Table 4 PhenX protocol changes implemented by sites (Continued)
know option given, question 10 put Did drinking ever cause you to have into table same with question
12 lead in, 13.12 which ones removed from table and just asked them to specify which ones
030400 Didn’t give definition or flashcards for size of a drink PMRP
010200 Added a Don’t Know option PMRP
010300 No changes PMRP
010400 No changes PMRP
060100 Added Your to Type & Age of Home, did not use 5. when did you move from there?, current pets
removed refused/don’t know option,
PMRP
010800 Changed from verify address to list your complete address PMRP
010100 Removed don’t know/refused option and about how old are you PMRP
011000 Removed refused option PMRP
010900 Removed don’t know/refused options PMRP
011300 Changed what in the question to other to match the selections PMRP
060700 To question 1 added in your current household, removed the refused/don’t know options. For who
smokes created a table to complete
PMRP
120500 Removed from the Composite International Diagnostic Interview from the section header, removed
refused/not asked options, if question 4 was yes, asked 4a didn’t skip to 5 as direction indicated, if no
skip to 5, Part II removed scoring
PMRP
010500 Removed refused don’t know from first question and refused from second question PMRP
040100 Added 2 more lines for sister, brother, daughter, son PMRP
010700 Removed refused/don’t know options PMRP
020600 Added Which hand do you use to: to the table, added only to the right hand and left hand column
header
PMRP
011500 Removed refused option, added our Badger Care PMRP
020704 Removed refused/don’t know options, listed as ____FEET ____INCHES PMRP
130300 Started A. at SUDDEN LOSS OR CHANGE OF SPEECH, removed don’t know from question 3, 5e had
question read If more than one problem with you speech, which of these most closely describes the
problem with your speech?, in 6 removed INCLUDE ALL THAT APPLY and READ ALL directions, I THINK
INCORRECTLY CHANGED SKIP IN 9 SHOULD HAVE ASKED 9A FOR BOTH EYES AND ASKED FOR RIGHT
AND LEFT INSTEAD, in 10 removed INCLUDE ALL THAT APPLY, 11 11a 14 15 removed don’t know,
PMRP
011400 Made into a table and added space for one more person PMRP
120400 No changes PMRP
010600 Removed refused option PMRP
060800 Changed I to we, bolded ask about your full brothers and sisters, removed NA option in question 2, to 3
added List oldest to youngest, putting yourself in the birth order, changed name to initials, removed NA
option, last column reads How old are they now/were they when he/she died
PMRP
030900 Removed don’t know/refused option PMRP
030600 Removed don’t know refused options, removed skip after question 2, if question 1 no went to smoke
exposure section,
PMRP
031000 But b. at the end of the 6 questions with direction to return to answer for max use if appropriate, PMRP
030800 Changed directions to read The following are three sections. Section A is for Every-Day Smokers. Section
B is people who are Some-Day Smokers. Section is for Former Smokers. Removed don’t know/refused
options.
PMRP
030700 Removed skip directions and asked both question of all smokers, removed don’t know/refused options PMRP
150900 Removed scoring table PMRP
061300 Added don’t know option to direct to question if don’t know exact age question, and reworded the
headings in the table to read on a typical weekday in the summer, on a typical weekend day in the
summer, For how many months a year did you usually have a tan, row headings read when you were in
your (teens or twenties or thirties or the past ten years) about how many hours did you generally spend
in the mid-day sun.
PMRP
021502 Requested in lbs. PMRP
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site:
To gain better understanding of social, behavioral and
genetic factors and their interactions may affect healthy
longevity, as well as to provide database for academic
research, health and aging policy analysis, the Chinese
Longitudinal Healthy Longevity Survey (CLHLS) con-
ducted about 80,000 face-to-face interviews with par-
ticipants in 1998, 2000, 20002, 2005, and 2008/2009,
respectively. Among about 80,000 interviews conducted
in the CLHLS 1998-2008/2009 five waves, 14,376 inter-
views were with centenarians, 18,938 with nonagenarians,
20,823 with octogenarians, 14,285 with young-old aged
65–79, and 10,962 with middle-age adults aged 35–64.
Data on mortality and health status before dying for the
17,649 elders aged 65–110 who died between follow-up
waves were collected in interviews with a close family
member of the deceased. The survey areas covered 22
provinces sharing 85 percent of total population in China.
The CLHLS datasets have been publicly available and
widely applied in aging studies by scholars around the
world.
In the CLHLS 1998 baseline survey and the 2008/2009
5th wave, DNA (blood and saliva) samples were collected
from 18,093 interviewees, including 3,193 centenarians,
4,821 nonagenarians, 4,076 octogenarians, 3,441 young-
old aged 65–79, and 2,619 adults aged 40–64.
Supported by the administrative supplement awarded
by The National Human Genome Research Institute, the
CLHLS team added 13 PhenX measures (including 32
data items) in our CLHLS 2011/2012 new wave. These
additional relevant standard phenotypic and environmen-
tal exposure measures related to healthy aging selected
from the NIH PhenX Toolkit will be used together with
other internationally-standardized data which have been
collected in CLHLS to address scientific questions on the
effects of genetic, social, behavioral, environmental factors
and their interactions on healthy aging at old ages.
The CLHLS study protocols (such as the informed con-
sensus forms and other relevant materials) was reviewed
and approved by the Institutional Review Boards of Duke
University and Peking University.
In addition to the site-specific projects outlined, cross-
network analyses are being undertaken for three projects
where two or more sites have collected the same PhenX
measures. Data harmonization for race/ethnicity was under-
taken across all seven sites. This measure was chosen be-
cause it was being used by all sites and several sites had
more than one measure used. Also, race/ethnicity is im-
portant for gene/environment analyses and the adminis-
trative supplement was specifically made available to
support gene/environment studies. The process employed
to harmonize the measures was first to compare the ques-
tions asked and the mode of administration. The PhenXToolkit measures were considered to be the common
measure for harmonization. The next step was to deter-
mine if the race/ethnicity categories were the same
for all sites. The category “other” served as the common
denominator where sites did not have the same level of
detail. Finally, variable names and codes were checked for
consistency.
Results
Study-specific protocols and data will eventually be
available in dbGaP for all of the PhenX RISING sites.
The various implementation strategies employed across
the sites and different study populations resulted in differ-
ent response rates and knowledge gained (Table 4). Site-
specific experiences follow.
Asian Indian Diabetic Heart Study/Sikh Diabetes Study
(AIDHS/SDS)
Quantification of serum biomarkers using PhenX Toolkit
measures were performed on frozen serum samples of
participants with genotyping data available from GWAS.
Informed consent was obtained from each individual upon
initial inclusion into these investigations for participation
in genetic and biomarkers study therefore no additional
contact was required for these investigations. Results for
each biomarker were included in an extensive database
for analysis. Enrichment of GWAS data with additional
biomarkers could lead to identification of variants regulat-
ing important metabolic pathways through cross-study
analysis.
Two planned assays were not run because they would
have used too much of the remaining biological sample.
After discussion with RTI, ranges of sample volume re-
quirements was added to the PhenX Toolkit.
Our study strongly recommends biomarker assay
optimization (especially those measured using differ-
ent platforms) to reduce inter-study variability.
Detroit Neighborhood Health Study
The PhenX Toolkit measures were incorporated into the
fourth interview wave of the DNHS. The PhenX Toolkit
measures required formatting for telephone administra-
tion and CATI programing from their original written
application. Questions were re-numbered to fit into the
existing annual survey structure. Response coding was
adjusted to match existing survey codes for consistency.
The PhenX Toolkit measure for Annual Family Income
was not included in the final version of the survey. The
Annual Family Income measure requires the interviewer
to have information on current poverty levels from the
U.S. Census Bureau. We found the question structure was
not compatible with certain poverty threshold scenarios
based on 2008 poverty data for Detroit, MI. For example,
it would be possible for a participant to have an annual
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threshold based on their family size. As a consequence,
their response would not trigger the poverty threshold spe-
cific income component of the PhenX question because
they fell into a previously asked income category. Due to
this inconsistency and potential for incorrect classification,
we reverted to an annual family income question structure
successfully implemented in previous survey waves.
We also found it necessary to change the administra-
tion of substance use questions for both the lifetime use
and 30-day frequency. These questions were originally
developed to be asked at an in-person interview and the
materials on the PhenX Toolkit include a “flashcard” de-
scribing the various types of substances included in this
measure. To effectively adapt these questions for tele-
phone administration and determine licit from illicit use,
we modified the structure to ask: 1- if the participant had
ever used the substance in their lifetime, 2- if the partici-
pant answered yes to #1 they were asked the 30-day fre-
quency of use, 3- if the participant answered yes to #1,
they were asked if they ever used the substance illicitly in
their lifetime for the drug categories sedatives, tranquil-
izers, painkillers, stimulants, and marijuana, 4-if the par-
ticipant answered yes to #3, they were asked the 30-day
frequency of illicit use, again for the drug categories seda-
tives, tranquilizers, painkillers, stimulants, and marijuana.
All reported use of the drug categories cocaine, hallucino-
gens, inhalants/solvents, and heroin was assumed to be
illicit as they are controlled substances. These alterations
kept the essence of original measure yet tease out the dif-
ference between licit and illicit use in a telephone inter-
view format.
The survey was administered to participants by Abt SRBI
(New York, NY) beginning in September 2011 and con-
cluded in February 2012. The average administration
length was 32.3 minutes and a response rate of 80% (845
of 1050) was achieved.
The Aiello Group identified some limitations associ-
ated with a few PhenX toolkit measures in their survey
when applied to their population of participants in the
“Detroit Neighborhood Health Study”. Certain validated
measures, such as substance use and annual family in-
come, had to be altered to be successfully administered
by telephone in the DNHS population. Though the
Aiello Group supports the use of standardized measures
to foster collaboration and analysis between studies, fur-
ther refinement of the PhenX Toolkit measures will be
needed to reflect the diverse settings in which they may
be used, such as phone, personal computer, or in-person
interviews.
Duke University Imaging Genetics Study
The response rate for PhenX measures in this study
was 100%. The high response rate was likely due to theconditions of the study. Participants required minimal
additional instruction from research staff, suggesting that
online administration of the PhenX measures is viable.
The PhenX Toolkit measures required time to format
for computerized administration, including automated
skip-logic (i.e., creating computerized instructions to ig-
nore some questions if previous answers suggest they
are irrelevant) and custom formatting of some items.
This initial investment of resources resulted in signifi-
cant advantages over paper administration however once
the questionnaires were converted to electronic format.
The value of computerized administration increases with
sample size, such that in any large scale study, it is diffi-
cult to imagine using a paper format unless absolutely
required. We would like to emphasize however that
PhenX measures requiring an interviewer were generally
avoided for this study and would pose unique challenges
to computerized administration.
Marshfield Clinic Personalized Medicine Research Project
The strategy of two mailings with a modest financial in-
centive has been used successfully in Marshfield previ-
ously for self-administered questionnaires [11]. With the
32-page PhenX self-administered questionnaire, this strat-
egy resulted in a 70% response rate.
The PhenX Toolkit measures required substantial time
to format for self-administration (Table 4). The instruc-
tions for a person to administer the questions and the
instructions for scoring some of the sections had to be
removed. Distracting notations for data entry were de-
leted. Response order was changed to be consistent be-
tween questions, such that “yes” always came before “no”.
“Refused” was deleted as a response category. Numbering
was changed to reflect the total number of questions in-
cluded. RTI responded by creating an option to select
“self-administered” within the PhenX toolkit when creat-
ing the data worksheets.
A number of rules for coding non-standard responses
were developed and shared with RTI International and
NHGRI program staff to be incorporated into the Phenx
Toolkit. Where subjects entered numbers that were not
integers and the PhenX measure only allowed for inte-
gers, numbers were rounded up. When subjects indi-
cated two education levels, the highest was selected for
data entry. Improbable responses such as a height of 11
feet were changed to missing data. In the section with
questions about health problems related to drinking, if a
health problem not clearly related to drinking (such as a
hiatal hernia) was indicated, that response was not used.
In the depression symptom assessment, if more than
one response category was entered the more severe level
was entered. If number ranges were given, the mid-point
of the range was entered and rounded up if an integer
was required.
McCarty et al. BMC Medical Genomics 2014, 7:16 Page 13 of 18
http://www.biomedcentral.com/1755-8794/7/16In the data cleaning process, several genders errors were
discovered. After checking the medical records for these
subjects, it became clear that the spouse of the intended
subject had completed the PhenX questionnaire.
One of the biggest issues I think we had discussed in
the beginning was the way the Domains had to be trans-
ferred from their original form to the questionnaire
form. (very time and labor intensive).
The Domains could have been written in a more basic
easy to follow manner and then ready to be inserted in
to questionnaire form. To be very explicit and try to
eliminate the replies that result in such outliers.
Scoring was huge issue. This again should be more
consistent across all the sites. Our site overcame the in-
consistent answers by looking at each of the situations
individually and creating a rule for each situation.
Pediatric Imaging, Neurocognition and Genetics (PING)
As previously noted, strategies for acquiring data from
participants who already completed the rest of their
PING assessment varied by site. As such, response rates
also varied by site. Of the original 585 participants tar-
geted at the 6 participating PING sites, 286 completed
the PhenX measures (49%). The UC San Diego site
added 77 CBQ parent-report measures in the 3 to 7 age
range, for a total 361 cases (2 participants who com-
pleted the CBQ at age 7 were also among the partici-
pants who completed the web-based assessment when
they turned 9). The length of the online study varied ac-
cording to the age-based study arm the participant
qualified for, but completion time ranged from 20 mi-
nutes for children ages 9–10 to 1.5 hours for adolescents
who endorsed use of a variety of substances.
Creation of the study in Assessment Center had a
number of strengths and weaknesses. Assessment Center
was designed for the purpose of secure data collection,
and this made it an ideal medium for collecting this
small amount of data and adding it to the larger set of
data that was already collected for these participants.
Creation of the short form instruments was simple, and
once an instrument was created, it could be placed in as
many study arms as necessary, or even shared with other
studies in Assessment Center. Creation of the substance
use forms was somewhat more difficult. The skip logic
options in Assessment Center are relatively basic, allow-
ing the instrument only to skip ahead on the basis of
specific responses to the current item. It would not
allow for more complex branching involving decisions
based on responses to previous questions. Therefore, it
was sometimes necessary to change the order of items
or add additional items to allow the instrument to flow
continuously from beginning to end. In addition, some
of the substance use questionnaires came with reference
materials describing alcoholic beverages and substancesfor the participant. Such materials could not be provided
on-screen with the relevant questions using Assessment
Center. Because of this, a PDF file was created with the
reference materials and emailed to the relevant partici-
pants when sending them the study link.
For the purpose of ongoing quality assurance, data
were scored using the PhenX protocol. One issue that
was discovered relating to online data collection was
that some items were skipped. Items that were skipped
by design due to the program’s skip logic were denoted
by missing values in the output table. However, skipped
items for which a response was expected were denoted
with the word “SKIP” in the output. When a participant
skipped an item, there was no way of knowing if this
was accidental or whether s/he chose to skip it, and if
so, why. Some may have skipped items because they did
not feel comfortable answering, but others may have
skipped because they did not understand the question.
This may be one potential drawback to collecting data on-
line rather than in a lab where a researcher can answer any
questions and ensure that any missing data was intentional
and/or unavoidable. Because most of the scoring instruc-
tions for the PhenX short form measures involve summing
items across subdomains, missing items heavily impacted
scores. As such, it may be necessary to develop scoring
protocols that either compute mean scores rather than
summed scores, or impute missing data.
A number of challenges arose in the implementation
of the PhenX RISING supplement to the PING study.
Because PING is itself a multisite initiative taking place
at 9 different sites across the U.S., we ran into a number
of problems throughout the data collection and sharing
process. Each site had specific language regarding what
measures would be administered and how that data
could be shared in their consent forms and IRB proto-
cols, and this language was not standardized across sites.
Because the measures given through the PhenX RISING
initiative were added on to an already existing protocol
that was specific to each site, the process of amending
IRB protocols was time consuming. It turned out that it
was not feasible for each site to amend its IRB to accom-
modate the collection of PhenX RISING data. As a re-
sult, three of our nine sites opted not to participate in
PhenX RISING. Additionally, another two sites deter-
mined after data collection was complete that they were
unable to share the data that was collected. Because of
this, we would strongly recommend that multisite stud-
ies standardization their IRB protocols as early as pos-
sible, paying particularly close attention to data sharing
language.
Another challenge associated with PhenX data collec-
tion was that a large number of PING participants had
already completed their visit before the PhenX initiative
was implemented. As a result, we felt that the best chance
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sures was to offer the battery of questionnaires as an
online survey. We spent a great deal of time convert-
ing PhenX measures to Assessment Center, and we
ran into a number of problems with questionnaires
that used loops and skip logic. Overcoming these ob-
stacles took some time. This barrier and the IRB diffi-
culties described above were the primary reasons why
so many PING participants had participant had com-
pleted their visits by the time we were able to launch
PhenX data collection. Despite our efforts to make it as
easy as possible to respond to our PhenX questionnaires,
we ultimately overestimated the number of participants
from which we would be able to acquire the added PhenX
data. If we had our IRB issues resolved earlier, it would
have been very useful to have an already existing web-
based mechanism for acquiring data. One way of accom-
plishing this would be to have standard versions of these
questionnaires in Assessment Center.
In addition to the challenges described above, we also
learned a valuable lesson about the use of these mea-
sures in a developmental sample. The PhenX Toolkit
has a number of measures that have child and adult ver-
sions, and this is useful for studies with more narrow
age ranges. However, our sample ranged in age from 3
to 20. We were not able to find measures that could be
given across our entire age range. As a result, we ended
up with much smaller sample sizes than we had hoped
for many of the measures, even when taking the other
challenges we faced into consideration. Combining ver-
sions was often not possible because the administration
format and domain scores are often quite different. We
attempted to get around this to some extent by modify-
ing the wording of some questions so we could expand
the age range of a single form. However, to the extent
possible, it would be very helpful if some measures could
be identified for inclusion that span a wider age range
for children and adolescents.
UCLA Consortium for Neuropsychiatric Phenomics
UCLA Consortium for Neuropsychiatric Phenomics Par-
alleling other sites we found that the formatting of PhenX
measures to our unique Web-based platform involved
more effort than we would have hoped, particularly for
certain branching questionnaires. Given the high likeli-
hood that future studies may well move towards increas-
ing Web-based data acquisition, it may be useful to
consider developing a centralized Web-service that would
help better standardize the acquisition process and data
capture, because the current model is going to involve yet
another “translation” to integrate with other PhenX data
even though the data are designed to be compatible.
For the in-laboratory components of examination
(in our case, for neurocognitive phenotyping), we thinkstandardization would be enhanced if PhenX were to pro-
vide standard instructions and training guidelines. Our
group has extensive experience with the PhenX instru-
ments, but as we organized the training it became clear
that there are many “devils in the details” of test adminis-
tration training and quality assurance that we are familiar
with as a site primarily dedicated to cognitive assessment,
but sites with less experience aiming to “add on” some
cognitive phenotype measures will likely benefit from
more guidance. For example, the different vendors of the
psychological tests do not uniformly provide instructions
on key elements of the examination procedure including
stimulus presentation, response collection, and scoring of
ambiguous responses.
Chinese Longitudinal Healthy Longevity Survey (CLHLS)
The data entry and cleaning for the CLHLS 2011 survey
in all other sampled areas was completed. We have con-
ducted interviews with 7,375 surviving CLHLS partici-
pants aged 65+, and 4,918 interviews with a close family
member of the deceased CLHLS Participants aged 65+.
The response rate of our CLHLS 2011 survey is 86.1%,
lost-follow-up rate (mainly due to outmigration and the
interviewers could not find them any more) is 11.5%, and
the refusing rate is 2.4%. The refusal rate was fairly close
to that in previous waves, which may show that the newly
added 13 PhenX measures (with 32 data items) are in
general workable among Chinese elderly population. The
interview refusal rate among the Chinese elderly especially
the oldest-old was low. The low refusal rate likely is due
to the fact that the Chinese elders especially the oldest-old
in general like to talk to outside people, plus they stay at
home without a job or other duties. Many of the oldest-
old and their family members may also feel honored to
participate in survey interviews concerning healthy lon-
gevity, as they may be proud of being a member of a long-
lived group.
Age reporting of Han Chinese consisting of 94.4% of
the total sample of our CLHLS 2011 survey is acceptably
accurate, which is rather unique as compared to many
other developing countries. Acceptably accurate age
reporting among the Han Chinese elderly including the
oldest-old is due to their cultural tradition of memoriz-
ing their date of birth for determining important life
events such as dates of engagement, marriage, starting
to build a residential house, and even for long-distance
traveling. This has been confirmed previously [16]. We
have conducted evaluations of the data quality of the
CLHLS 2011 survey including the newly added PhenX
measures. The evaluation include assessments of mortal-
ity rate, proxy use, non-response rate, sample attrition,
reliability and validity of major health measures, and the
rates of logically inconsistent answers, with generally sat-
isfactory results compared to other major aging studies.
Table 5 Demographic data by site
Group Sample
size
Median age
and range
# Male Male median
age and range
Female median
age and range
African
American
White Asian American
Indian
Native
Hawaiian
More than
one race
Hispanic
Asian Indian Diabetic Heart Study/SIKH
Diabetes Study (AIDHS/SDS)
1782 53 936 53 52 0 0 1782 0 0 0 0
19-89 19-86 20-89
Chinese Longitudinal Healthy Longevity
Survey (CLHLS)
7375 85.6 3316 83.7 87.2 0 0 7375 0 0 0 0
65-113 65-111 65-113
Detroit Neighborhood Health Study 845 59.3 333 57.8 59.9 685 97 3 7 0 19 26
19.7-98.2 19.7-94.7 21.7-98.2
Duke University Imaging and Genetics 331 19.25 142 19.27 19.23 48 196 97 9 0 26 32
12.26-22 12.26-22 12.9-22
Marshfield Clinic Personalized Medicine
Research Project (PMRP)
2271 72.7 910 73.7 72.2 0 2192 4 0 0 8 12
54.1-101.7 54.6-96.1 54.1-101.7
Pediatric Imaging Neurocognition and
Genetics (PING)
398 12.92 204 13.58 12.00 47 266 102 23 34 127 110
3-22.7 3-22.7 3.17-22.58
UCLA Consortium for Neuropsychiatric
Phenomics
308 28.0 132 29 27 3 254 2 46 0 2 99
21-50 21-50 21-50
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formance, and functional limitations demonstrate that
the interviewees’ answers to questions concerning differ-
ent aspects of the same category are generally consistent.
The rates of logically inconsistent answers and incom-
plete data are relatively low. Careful assessments have
led us to believe that, similar to previous CLHLS waves,
the data quality of the CLHLS 2011 survey is generally
good. However, we realize that some problems also exist
in the datasets, which will be addressed in our forthcom-
ing technical reports.
As the first batch of the results of our CLHLS PhenX
study component, we have produced a 35-page report
including 34 tables containing the 34 data items in the
2011 CLHLS questionnaires corresponding to the 13
newly-added PhenX measures, supported by the NIH
administrative supplement grant awarded to CLHLS re-
search team. These PhenX measures are based on the
healthy-ageing relevant items from the internationally
well-known PhenX Toolkit (https://www.phenxtoolkit.
org/), and adopted to Chinese culture and social reality.
As previously planned, our CLHLS 2012 survey in 8
longevity areas (counties or cities) where the density of
centenarians is exceptionally high is still ongoing. We
adopts the same study protocol but with added more so-
phistic components in our 2012 survey in these 8 longev-
ity areas, as compared to the survey in the other sampled
areas of the 22 provinces surveyed in 2011. We expect to
complete all field work of face-to-face interviews around
the end of October in 2012 (note: Our previous fifth wave
of CLHLS was conducted in 2008/2009, and thus the
current sixth wave is in 2011/2012). We will conduct data
analysis on the relevant PhenX measures newly collected,
aiming at: (1) to enhance the interdisciplinary research of
genetics and its interactions with social and behavioral
factors; (2) to broaden the scope of our CLHLS study and
combine it with other investigations using the same or
similar PhenX measures to increase power and efficiency
of discoveries on effects of genetic, social, behavioral fac-
tors and their interactions on healthy aging.
As demonstrated in Table 5 by the large number of study
subjects representing diverse racial/ethnic groups, the
PhenX RISING network was able to successfully imple-
ment PhenX measures into ongoing studies in a relatively
short time frame (one-year administrative supplements to
parent grants).
Discussion and conclusions
There are a number of consortium efforts to standardize
phenotypic measures to facilitate large-scale data sharing
and comparison for genomic studies. The eMERGE net-
work has shown that electronic algorithms can be devel-
oped and applied to electronic medical records to produce
valid phenotypes for use in genome-wide associationstudies [12]. Similarly, the Phenotype Standardization
Project is developing valid phenotypes for pharmacoge-
netic studies of serious adverse drug reactions [17-19].
The goal of the PhenX RISING network was to evaluate
implementation of PhenX measures into ongoing genomic
studies. We have shown the PhenX measures to be useful
for large-scale studies linking genotypes and phenotypes
and we identified a number of issues in the use of the
PhenX Toolkit that were addressed to improve the Toolkit
for future users. Advantages include the large number of
measures employed and the diversity of administration
and study cohorts. The diversity could also be viewed as a
disadvantage because there was little replication for spe-
cific measures and study cohort types. Ongoing validation
efforts at many of the sites will provide information about
the accuracy of the data collected in various formats and
with any modifications implemented at the sites.
Several cross-network analyses are ongoing between the
groups that have collected the same PhenX measures. The
Data Use Agreement and the standardized PhenX mea-
sures will facilitate these collaborations. The within- and
between-group gene/environment analyses will be the ul-
timate test of the PhenX measures. Other researchers who
use the PhenX measures are encouraged to provide feed-
back to RTI for continual improvement of the Toolkit.
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